Drug Trial Radar · NCT01176565
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
Last checked: Nov 19, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,000
Actual
Start
May 15, 2011
Primary completion
Dec 21, 2015
Study completion Mar 8, 2016
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS); Medical University of South Carolina; Johns Hopkins University; University of Michigan; Neurocritical Care Research Network; National Cerebral and Cardiovascular Center, Japan; Japan Cardiovascular Research Foundation; Beijing Tiantan Hospital; China Medical University Hospital; University Hospital Heidelberg; Seoul National University Hospital
- First posted
- Aug 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset. 2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months. 3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans. 4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.
Conditions
- Intracerebral Hemorrhage
Interventions
Intravenous nicardipine hydrochlorideDrug
IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range. Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From RandomizationTime frame: 90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization
Locations
171 sites in 7 countries. Site status is shown where the registry gives one.
UAB Comprehensive Stroke Center
Birmingham, Alabama
Maricopa Medical Center
Phoenix, Arizona
Mayo Clinic Pheonix
Scottsdale, Arizona
Banner University Medical Center - South Campus
Tuscon, Arizona
Banner University Medical Center - University Campus
Tuscon, Arizona
Community Regional Medical Center of Fresno
Fresno, California
University of California San Diego
La Jolla, California
Long Beach Memorial Medical Center
Long Beach, California
Ronald Regan UCLA Medical Center
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Stanford University
Palo Alto, California
Sutter Roseville Medical Center
Roseville, California
UC Davis Medical Center
Sacramento, California
UCSF Medical Center
San Francisco, California
Good Samaritan Hospital
San Jose, California
Santa Clara Valley Medical Center
Santa Clara, California
Colorado Neurological Institute
Englewood, Colorado
Yale - New Haven Hospital
New Haven, Connecticut
Christiana Hospital
Newark, Delaware
University of Florida Gainesville
Gainesville, Florida
Baptist Medical Center Jacksonville
Jacksonville, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
University of South Florida, Tampa General Hospital
Tampa, Florida
Grady Memorial Hospital
Atlanta, Georgia
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
Eastern Idaho Medical Consultants
Idaho Falls, Idaho
Loyola University Medical Center
Maywood, Illinois
Advocate Christ Medical Center
Oak Lawn, Illinois
OSF Saint Francis Medical Center
Peoria, Illinois
Southern Illinois University Memorial Medical Center
Springfield, Illinois
Lutheran Hospital Indiana
Fort Wayne, Indiana
Parkview Hospital
Fort Wayne, Indiana
Kansas University Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
University of Louisville
Louisville, Kentucky
West Jefferson Medical Center
Marrero, Louisiana
Interim LSU Hospital
New Orleans, Louisiana
Tulane Medical Center
New Orleans, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.